Pediatric asthma: An unmet need for more effective, focused treatments
File(s)
Author(s)
Type
Journal Article
Abstract
Background
Despite remarkable advances in our understanding of asthma, there are still several unmet needs associated with the management of pediatric asthma.
Methods
A two‐day, face‐to‐face meeting was held in London, United Kingdom, on October 28 and 29, 2017, involving a group of international expert clinicians and scientists in asthma management to discuss the challenges and unmet needs that remain to be addressed in pediatric asthma.
Results
These unmet needs include a lack of clinical efficacy and safety evidence, and limited availability of non‐steroid‐based alternative therapies in patients <6 years of age. An increased focus on children is needed in the context of clinical practice guidelines for asthma; current pediatric practice relies mostly on extrapolations from adult recommendations. Furthermore, no uniform definition of pediatric asthma exists, which hampers timely and robust diagnosis of the condition in affected patients.
Conclusions
There is a need for a uniform definition of pediatric asthma, clearly distinguishable from adult asthma. Furthermore, guidelines which provide specific treatment recommendations for the management of pediatric asthma are also needed. Clinical trials and real‐world evidence studies assessing anti‐immunoglobulin E (IgE) therapies and other monoclonal antibodies in children <6 years of age with asthma may provide further information regarding the most appropriate treatment options in these vulnerable patients. Early intervention with anti‐IgE and non‐steroid‐based alternative therapies may delay disease progression, leading to improved clinical outcomes.
Despite remarkable advances in our understanding of asthma, there are still several unmet needs associated with the management of pediatric asthma.
Methods
A two‐day, face‐to‐face meeting was held in London, United Kingdom, on October 28 and 29, 2017, involving a group of international expert clinicians and scientists in asthma management to discuss the challenges and unmet needs that remain to be addressed in pediatric asthma.
Results
These unmet needs include a lack of clinical efficacy and safety evidence, and limited availability of non‐steroid‐based alternative therapies in patients <6 years of age. An increased focus on children is needed in the context of clinical practice guidelines for asthma; current pediatric practice relies mostly on extrapolations from adult recommendations. Furthermore, no uniform definition of pediatric asthma exists, which hampers timely and robust diagnosis of the condition in affected patients.
Conclusions
There is a need for a uniform definition of pediatric asthma, clearly distinguishable from adult asthma. Furthermore, guidelines which provide specific treatment recommendations for the management of pediatric asthma are also needed. Clinical trials and real‐world evidence studies assessing anti‐immunoglobulin E (IgE) therapies and other monoclonal antibodies in children <6 years of age with asthma may provide further information regarding the most appropriate treatment options in these vulnerable patients. Early intervention with anti‐IgE and non‐steroid‐based alternative therapies may delay disease progression, leading to improved clinical outcomes.
Date Issued
2019-02-01
Date Acceptance
2018-09-11
Citation
Pediatric Allergy and Immunology, 2019, 30 (1), pp.7-16
ISSN
1399-3038
Publisher
Wiley
Start Page
7
End Page
16
Journal / Book Title
Pediatric Allergy and Immunology
Volume
30
Issue
1
Copyright Statement
© 2018 The Authors. Pediatric Allergy and Immunology Published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000457444400002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Subjects
Science & Technology
Life Sciences & Biomedicine
Allergy
Immunology
Pediatrics
asthma management
omalizumab
pediatric asthma
unmet need
BONE-MINERAL DENSITY
INHALED CORTICOSTEROIDS
ALLERGIC-ASTHMA
PREDICTIVE-VALUE
IGE RESPONSES
DOUBLE-BLIND
CHILDREN
OMALIZUMAB
MANAGEMENT
CHILDHOOD
Publication Status
Published
Date Publish Online
2018-11-15